Logo

LXRX

Lexicon Pharmaceuticals, Inc.

LXRX

Lexicon Pharmaceuticals, Inc. • NASDAQ
$1.43 ▲ 0.00% (+0.00)
Market Cap $519.66 M
52w High $1.66
52w Low $0.28
Dividend Yield 0%
P/E -7.53
Volume 427.97K
Outstanding Shares 363.40M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $14.182M ▼ $26.359M ▲ $-12.769M ▼ -90.037% ▼ $-0.04 ▼ $-10.463M ▼
Q2-2025 $28.866M ▲ $24.921M ▼ $3.252M ▲ 11.266% ▲ $0.009 ▲ $5.746M ▲
Q1-2025 $1.262M ▼ $26.911M ▼ $-25.295M ▲ -2.004K% ▼ $-0.07 ▲ $-23.284M ▼
Q4-2024 $26.554M ▲ $33.358M ▼ $-33.766M ▲ -127.16% ▲ $-0.09 ▲ $-20.312M ▲
Q3-2024 $1.75M $65.372M $-64.811M -3.703K% $-0.18 $-60.123M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $115.95M ▼ $205.927M ▼ $85.768M ▼ $120.159M ▼
Q2-2025 $139.007M ▼ $225.583M ▼ $96.143M ▼ $129.44M ▲
Q1-2025 $194.839M ▼ $297.671M ▼ $174.639M ▲ $123.032M ▼
Q4-2024 $237.957M ▼ $298.42M ▼ $152.47M ▲ $145.95M ▼
Q3-2024 $258.369M $321.123M $142.611M $178.512M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-12.769M ▼ $0 ▼ $0 ▼ $0 ▲ $28.292M ▲ $0 ▼
Q2-2025 $3.252M ▲ $16.993M ▲ $15.483M ▼ $-45M ▼ $-12.524M ▼ $16.993M ▲
Q1-2025 $-25.295M ▲ $-43.778M ▼ $40.582M ▼ $-572K ▼ $-3.768M ▼ $-43.778M ▼
Q4-2024 $-33.766M ▲ $-21.491M ▲ $53.7M ▲ $-104K ▲ $32.105M ▲ $-21.965M ▲
Q3-2024 $-64.811M $-53.619M $53.469M $-916K $-1.066M $-53.926M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$30.00M ▲$10.00M ▼
Product
Product
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Lexicon is still very much a development‑stage company from a financial perspective. Revenue has been negligible over the last several years, only starting to tick up very recently, which suggests that commercial sales are at an early stage and not yet supporting the business. Operating losses and net losses have been consistent and sizeable each year, reflecting heavy spending on research, clinical development, and initial commercialization. The loss per share has stayed in a fairly narrow negative range, which indicates that, despite progress in the pipeline and product approvals, the business model is not yet close to break‑even. Overall, the income statement shows a company investing for future potential rather than one generating sustainable profits today.

Balance Sheet

Balance Sheet The balance sheet looks typical for a small biotech: modest assets, a meaningful but not extreme level of debt, and a relatively thin equity cushion. Cash levels have moved around, with some years of stronger liquidity and others much tighter, highlighting reliance on capital raises, partnerships, or milestone payments. Notably, equity swung from sharply negative a few years ago to positive again, suggesting a recapitalization or restructuring that cleaned up the balance sheet. Even so, the company’s financial foundation remains delicate, and its resources need to be carefully managed given continuing losses and the capital intensity of late‑stage drug development and commercialization.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing cash burn to fund R&D, clinical trials, and the early commercial build‑out. There is essentially no spending on physical assets, so free cash flow closely mirrors operating cash outflows. This pattern underscores that Lexicon depends on external funding sources—equity, debt, and partnership payments—to sustain its programs. Until one or more products scale meaningfully in the market or larger partnership inflows materialize, investors should expect continued pressure on cash and the need for careful liquidity management.

Competitive Edge

Competitive Edge Lexicon’s competitive position is built less on its current revenue base and more on its scientific platform and unique assets. The company competes in extremely crowded and well‑resourced therapeutic areas—heart failure, diabetes, pain, and obesity—where large pharmaceutical players dominate. However, its dual‑mechanism heart failure drug (INPEFA / sotagliflozin) offers a differentiated mode of action versus standard SGLT2 drugs, potentially allowing it to carve out a niche if clinical and real‑world data continue to support added benefits. In neuropathic pain, its non‑opioid, first‑in‑class approach could stand out if late‑stage trials succeed, given the strong need for safer pain treatments. The partnership with Novo Nordisk in obesity is a strong external validation of Lexicon’s discovery engine, but it also highlights that Lexicon will likely rely on larger partners to fully compete in big, global markets.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Lexicon’s story. The company’s gene‑knockout platform and LexVision database give it a distinctive way to discover and validate drug targets, backed by many years of accumulated genetic and disease biology know‑how. This has already produced several first‑ or best‑in‑class candidates: a dual SGLT1/2 heart failure drug, a novel AAK1 inhibitor for neuropathic pain, and an obesity candidate now in the hands of Novo Nordisk. R&D intensity is high and is the main driver of financial losses, but it has created a pipeline that targets large, unmet medical needs. The key uncertainties are the usual ones for biotech: clinical risk, regulatory outcomes, and the ability to convert scientific wins into commercial traction at scale.

Summary

Lexicon is a science‑driven biotech transitioning from pure R&D toward early commercialization, with financials that still look firmly like a development‑stage company: minimal revenue, persistent losses, and ongoing cash burn. The balance sheet has improved from a very weak position but remains relatively thin, leaving the company sensitive to funding conditions and dependent on external capital and partnerships. Strategically, Lexicon’s edge lies in its gene‑based discovery platform and the differentiated mechanisms of its key programs, which have attracted a major partner in obesity and produced an approved cardiovascular product plus a promising non‑opioid pain candidate. The upside case centers on successful late‑stage trials, regulatory progress, and stronger product uptake, while the main risks are scientific setbacks, slow commercialization in markets dominated by larger competitors, and the need for continued financing. Overall, this is a high‑risk, high‑uncertainty profile typical of small, innovation‑focused biopharmaceutical firms.

NEWS

November 25, 2025 · 8:30 AM UTC

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Read more

November 11, 2025 · 8:30 AM UTC

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Read more

November 8, 2025 · 2:30 PM UTC

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Read more

November 6, 2025 · 7:30 AM UTC

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Read more

November 4, 2025 · 8:30 AM UTC

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Read more